The World Health Organization (WHO) has taken an important step toward strengthening global regulatory convergence in the medical device sector. In July 2026, WHO published its transitional list of WHO Listed Authorities for Medical Devices (tWLAs-MD), recognizing only 12 national regulatory authorities and regional regulatory systems worldwide for their demonstrated regulatory oversight capacity. Brazil’s National Health Surveillance Agency (ANVISA) is among this select group, alongside organizations such as the U.S. Food and Drug Administration (FDA), Health Canada, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Australia’s Therapeutic Goods Administration (TGA), Swissmedic, and the European Medical Devices Regulatory Network.
For manufacturers seeking access to the Brazilian market, this recognition is more than a symbolic achievement. It reinforces ANVISA’s position as a globally trusted regulator and highlights the growing importance of regulatory reliance pathways that can significantly accelerate market entry for eligible medical technologies.
Understanding the WHO Listed Authority Framework
The publication of the tWLAs-MD list forms part of WHO’s broader transition away from the traditional concept of “Stringent Regulatory Authorities” (SRAs) toward the more comprehensive WHO Listed Authority (WLA) framework. The objective is to establish a transparent and globally recognized system for identifying regulators that consistently demonstrate strong regulatory performance, governance, scientific expertise, and oversight capabilities.
According to WHO, the transitional list serves as an interim mechanism to facilitate regulatory reliance while the permanent WLA designation process for medical devices is being finalized. The list was specifically created to support collaboration among regulators and encourage countries to leverage the assessments and decisions of trusted authorities, reducing duplication of effort and improving access to safe and effective health technologies.
In practical terms, inclusion on this list sends a clear message to governments, regulators, procurement agencies, and industry stakeholders worldwide: decisions made by these authorities can be relied upon with greater confidence.
Why ANVISA’s Recognition Matters
ANVISA’s inclusion among only 12 recognized authorities reflects the significant evolution of Brazil’s regulatory system over the past decade. The agency has progressively aligned its practices with international standards, strengthened participation in global regulatory forums, implemented risk-based approaches, and expanded the use of reliance and convergence mechanisms.
For medical device companies, this recognition confirms what many in the industry have already observed: ANVISA has become one of the world’s leading regulatory agencies for healthcare products and an increasingly influential authority within Latin America.
The designation may also contribute to greater international acceptance of ANVISA’s assessments and decisions, supporting future opportunities for regulatory cooperation and streamlined market access across multiple jurisdictions. As global regulators continue to embrace reliance models, trusted authorities such as ANVISA are expected to play an increasingly prominent role in facilitating access to innovative technologies worldwide.
The Direct Impact on Medical Device Registration in Brazil
Perhaps the most immediate relevance for manufacturers lies in how this development aligns with ANVISA’s existing reliance mechanisms for higher-risk medical devices.
Brazil has already established pathways that allow ANVISA to conduct optimized reviews for certain Class III and Class IV medical devices when those products have previously received approvals from recognized Equivalent Foreign Regulatory Authorities (EFRAs). These pathways are designed to reduce unnecessary duplication of regulatory assessments while maintaining Brazil’s high standards for safety, efficacy, and quality.
Through reliance-based reviews, ANVISA can leverage prior evaluations performed by trusted foreign regulators, focusing its resources on aspects that are particularly relevant to the Brazilian market. This approach can lead to substantially shorter review timelines compared with traditional registration routes.
The WHO recognition further validates the philosophy behind these mechanisms. If global regulators are being encouraged to place greater trust in assessments performed by authorities with demonstrated regulatory maturity, ANVISA’s position as a recognized tWLA-MD strengthens confidence in Brazil’s own reliance framework.
Opportunities for Global Manufacturers
For companies that already hold approvals in jurisdictions such as the United States, Canada, Australia, the European Union, Switzerland, the United Kingdom, Japan, Singapore, or other recognized regulatory systems, the Brazilian market may be more accessible than many organizations realize.
However, successfully leveraging regulatory reliance requires more than simply presenting an existing approval certificate. Manufacturers must carefully evaluate:
- Product classification and eligibility criteria.
- Alignment between the approved product and the version intended for Brazil.
- Technical documentation requirements.
- Labeling and language adaptations.
- Good Manufacturing Practice (GMP) considerations.
- Regulatory strategy across multiple Latin American markets.
A well-designed reliance strategy can significantly reduce regulatory burden and accelerate patient access. Conversely, inappropriate use of reliance pathways or gaps in submission planning can create delays and diminish the expected benefits.
Brazil’s Growing Role in Regulatory Convergence
ANVISA’s inclusion in the WHO transitional WLA list also reflects a broader trend: Brazil is becoming an increasingly important participant in the global movement toward regulatory convergence.
Around the world, regulators are facing growing pressures to evaluate increasingly complex technologies while operating with finite resources. Reliance models offer a practical solution by allowing authorities to leverage trusted assessments rather than repeating the same scientific review multiple times. This approach can improve efficiency, strengthen regulatory oversight, and accelerate access to innovative healthcare products.
As one of the regulators now recognized by WHO for its medical device oversight capabilities, ANVISA is well positioned to contribute to this evolving international ecosystem.
Strategic Considerations for Companies Entering Brazil
Manufacturers planning a Brazilian market entry should view this WHO recognition not simply as a regulatory milestone, but as a strategic opportunity.
Organizations with products already authorized by leading global regulators may be able to take advantage of optimized regulatory routes, potentially shortening timelines and improving predictability. At the same time, success depends on building the right strategy from the outset, identifying the most appropriate registration pathway, and ensuring that technical documentation is structured to maximize the benefits of reliance.
For companies seeking growth in Brazil and across Latin America, regulatory planning is increasingly becoming a competitive advantage rather than a purely compliance-driven activity.
How ClarkeModet Can Help
At ClarkeModet, we support medical device manufacturers throughout the entire registration lifecycle across Latin America. Our regulatory specialists help companies assess eligibility for reliance pathways, develop robust registration strategies, prepare compliant submissions, and manage interactions with health authorities.
As regulatory convergence continues to gain momentum, manufacturers that effectively leverage trusted approvals and reliance mechanisms will be best positioned to bring innovative, safe, and validated technologies to patients faster.
ANVISA’s recognition by WHO is another clear signal that Brazil’s regulatory system is becoming more integrated into the global regulatory landscape—and for medical device companies, that creates meaningful opportunities to accelerate market access when the right strategy is in place.